Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ: VTRS), a deal that extends Viatris’s exclusive commercialization rights to sotagliflozin in all markets outside the United States and Europe across all indications. Lexicon Pharmaceuticals retains the exclusive rights to commercialize sotagliflozin within the US…